Difference between revisions of "IVAX Corporation"

From Powerbase
Jump to: navigation, search
Line 5: Line 5:
 
==People==
 
==People==
 
*[[Isaac Kaye]]
 
*[[Isaac Kaye]]
−
==Aquisitions==
+
 
 +
In 2003, the following people are reported as serving IVAX<ref><i>FD (Fair Disclosure) Wire</i> 'Q1 2003 Ivax Earnings Conference Call - Final'. 24th April 2003</ref>...
 +
* [[Dan Weiner]] - Senior Vice President for Global Clinical Development
 +
* [[Steve Marcus]] - Senior Vice President for Proprietary Pharmaceutical Business Development.
 +
* [[Nick Vodar]] - Director of Drug Discovery and the Director of IVAx's Institute for Drug Research in Budapest, Hungary.
 +
* [[Betty Amos]] - Board member
 +
* [[Mitch Medique]] - Board member. Medique also serves on the board of several public companies (including [[National Semiconductor]] and [[Carnival Corporations]]).
 +
* [[Burt Pitt]]. Pitt is also a professor of cardiology at the University of Michigan School of Medicine. 
 +
 
 +
==Aquisitions and Partnerships==
 
In 2004, IVAX is reported to have aquired [[ChemSource Corporation]] (which is based in Puerto Rico)<ref> <i>Plunkett's Health Care Industry Almanac</i>. 'IVAX Corporation.' January 2004</ref> .
 
In 2004, IVAX is reported to have aquired [[ChemSource Corporation]] (which is based in Puerto Rico)<ref> <i>Plunkett's Health Care Industry Almanac</i>. 'IVAX Corporation.' January 2004</ref> .
  
 
ChemSource is reported to have 'recently entered into a license agreement with [[Novartis]] Pharma AG to utilize the patented multi-dose dry powder inhaler, Airmax, for Novartis's trademarked medicines Foradil and Miflonide in the European Union and certain other countries'<ref> <i>Plunkett's Health Care Industry Almanac</i>. 'IVAX Corporation.' January 2004</ref>.
 
ChemSource is reported to have 'recently entered into a license agreement with [[Novartis]] Pharma AG to utilize the patented multi-dose dry powder inhaler, Airmax, for Novartis's trademarked medicines Foradil and Miflonide in the European Union and certain other countries'<ref> <i>Plunkett's Health Care Industry Almanac</i>. 'IVAX Corporation.' January 2004</ref>.
  
−
In July 2003, <i>Business Wire</i> reports that IVAX 'received the first of a series of payments from [[B Braun Melsungen]] AG, under a number of agreements, for certain patent and product rights and for settlement of litigation'<ref><i>Business Wire</i> 'IVAX Reports Increased Revenues and Net Income for 2nd Quarter of 2003; 2Q2003 Net Revenues Up 22% to $343 Million, Net Income Up 30% to $41.3 Million' 30th July 2003. Miami</ref>.
+
In 2002, it is reported that IVAX 'established a company in France by acquiring [[Merck]] Sharp & Dohme's portfolio of generic products there<ref><i>FD (Fair Disclosure) Wire</i> 'Q1 2003 Ivax Earnings Conference Call - Final'. 24th April 2003</ref>.
 +
 
 +
==Litigation==
 +
In July 2003, <i>Business Wire</i> reports that IVAX 'received the first of a series of payments from [[B Braun Melsungen]] AG, under a number of agreements, for certain patent and product rights and for settlement of litigation'<ref><i>Business Wire</i> 'IVAX Reports Increased Revenues and Net Income for 2nd Quarter of 2003; 2Q2003 Net Revenues Up 22% to $343 Million, Net Income Up 30% to $41.3 Million' 30th July 2003. Miami</ref>. No further details were disclosed.
 +
 
 +
In 2003, [[Thomas Beier]], Senior Vice President and Chief Financial Officer for IVAX reported 'Operating expenses' which included a $6.6 million legal settlement<ref><i>FD (Fair Disclosure) Wire</i> 'Q1 2003 Ivax Earnings Conference Call - Final'. 24th April 2003</ref>. No further details were disclosed.
  
 
==Brands, Divisions and Affiliates==
 
==Brands, Divisions and Affiliates==
−
*[[Norton Hea
+
*[[Norton Healthcare]]
 
In 2004, <i>Plunkett's Health Care Industry Almanac</i> reports the following 'Brands/Divisions/Affiliates' of IVAX<ref> <i>Plunkett's Health Care Industry Almanac</i>. 'IVAX Corporation.' January 2004</ref>...  
 
In 2004, <i>Plunkett's Health Care Industry Almanac</i> reports the following 'Brands/Divisions/Affiliates' of IVAX<ref> <i>Plunkett's Health Care Industry Almanac</i>. 'IVAX Corporation.' January 2004</ref>...  
 
* [[Airmax]]
 
* [[Airmax]]

Revision as of 13:33, 4 June 2008

The Ivax Corporation is a huge Florida-based health company. Norton Healthcare, the largest generic drugs company in Britain, is a subsidiary of IVAX. Isaac Kaye earned $550,301 at IVAX in 1998 (plus share options worth up to $1.5 million) and $521,520 in 1997.[1]. In 2006 IVAX was aquired by Teva which is described as 'Israel's largest company'.[2] The aquisition is reported to have created 'the world's largest generics company'.[3].

Kaye is reported to have stepped down as chairman of Norton Healthcare in 2003[4]. Plunkett's Health Care Industry Almanac reports IVAX profits totalling $243,200,000 for 2001, $131,000,000 for 2000 and $70,700,000 for 1999. Their sales totals were $1,215,400,000, $793,400,000, and $656,500,000 respectively.

People

In 2003, the following people are reported as serving IVAX[5]...

  • Dan Weiner - Senior Vice President for Global Clinical Development
  • Steve Marcus - Senior Vice President for Proprietary Pharmaceutical Business Development.
  • Nick Vodar - Director of Drug Discovery and the Director of IVAx's Institute for Drug Research in Budapest, Hungary.
  • Betty Amos - Board member
  • Mitch Medique - Board member. Medique also serves on the board of several public companies (including National Semiconductor and Carnival Corporations).
  • Burt Pitt. Pitt is also a professor of cardiology at the University of Michigan School of Medicine.

Aquisitions and Partnerships

In 2004, IVAX is reported to have aquired ChemSource Corporation (which is based in Puerto Rico)[6] .

ChemSource is reported to have 'recently entered into a license agreement with Novartis Pharma AG to utilize the patented multi-dose dry powder inhaler, Airmax, for Novartis's trademarked medicines Foradil and Miflonide in the European Union and certain other countries'[7].

In 2002, it is reported that IVAX 'established a company in France by acquiring Merck Sharp & Dohme's portfolio of generic products there[8].

Litigation

In July 2003, Business Wire reports that IVAX 'received the first of a series of payments from B Braun Melsungen AG, under a number of agreements, for certain patent and product rights and for settlement of litigation'[9]. No further details were disclosed.

In 2003, Thomas Beier, Senior Vice President and Chief Financial Officer for IVAX reported 'Operating expenses' which included a $6.6 million legal settlement[10]. No further details were disclosed.

Brands, Divisions and Affiliates

In 2004, Plunkett's Health Care Industry Almanac reports the following 'Brands/Divisions/Affiliates' of IVAX[11]...

References

  1. ↑ Ref needed
  2. ↑ Teva, IVAX Acquisition, accessed 23 May 2008
  3. ↑ Maguire K (2002) Profile:Isaac Kaye The Guardian 13th April 2002. Accessed 4th April 2008
  4. ↑ Brogan, B. & Gysin, C. (2008) Hain faces sack in sleaze inquiry; He could be barred - but Brown might fire him first. The Daily Mail (London). 12th January 2008
  5. ↑ FD (Fair Disclosure) Wire 'Q1 2003 Ivax Earnings Conference Call - Final'. 24th April 2003
  6. ↑ Plunkett's Health Care Industry Almanac. 'IVAX Corporation.' January 2004
  7. ↑ Plunkett's Health Care Industry Almanac. 'IVAX Corporation.' January 2004
  8. ↑ FD (Fair Disclosure) Wire 'Q1 2003 Ivax Earnings Conference Call - Final'. 24th April 2003
  9. ↑ Business Wire 'IVAX Reports Increased Revenues and Net Income for 2nd Quarter of 2003; 2Q2003 Net Revenues Up 22% to $343 Million, Net Income Up 30% to $41.3 Million' 30th July 2003. Miami
  10. ↑ FD (Fair Disclosure) Wire 'Q1 2003 Ivax Earnings Conference Call - Final'. 24th April 2003
  11. ↑ Plunkett's Health Care Industry Almanac. 'IVAX Corporation.' January 2004
Retrieved from "https://powerbase.info/index.php?title=IVAX_Corporation&oldid=60814"